A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Clinical trial NCT03432286 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03432286
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-14
- Primary completion
- 2025-11-14
- Enrollment
- 533
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.